Abstract
The peroxisome proliferator-activated receptor –γ (PPARγ) has been identified in a wide range of cancers, including brain, breast, colon, stomach and lung cancers. It belongs to the thyroid/ steroid hormone receptors superfamily. Binding with their special ligands, PPARγ plays important roles in regulating transcription of their target genes. PPARγ activation suppresses the growth of the tumor cells, implicating the anti-tumor potential of PPARγ ligand. Tumors in the nervous system are among the most devastating cancers. This review highlights key advances in understanding the effects of PPARγ ligands in the treatment of tumors in the nervous system.
Keywords: Anti-tumor, chemoprevention, glioblastoma, nervous system, neuroblastoma, peroxisome proliferator-activated receptor γ, thiazolidinediones (TZDs).
Current Stem Cell Research & Therapy
Title:Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Volume: 11 Issue: 3
Author(s): Yun Shen, Yun Lu, Fang Yu, Chuntie Zhu, Hua Wang and Jing Wang
Affiliation:
Keywords: Anti-tumor, chemoprevention, glioblastoma, nervous system, neuroblastoma, peroxisome proliferator-activated receptor γ, thiazolidinediones (TZDs).
Abstract: The peroxisome proliferator-activated receptor –γ (PPARγ) has been identified in a wide range of cancers, including brain, breast, colon, stomach and lung cancers. It belongs to the thyroid/ steroid hormone receptors superfamily. Binding with their special ligands, PPARγ plays important roles in regulating transcription of their target genes. PPARγ activation suppresses the growth of the tumor cells, implicating the anti-tumor potential of PPARγ ligand. Tumors in the nervous system are among the most devastating cancers. This review highlights key advances in understanding the effects of PPARγ ligands in the treatment of tumors in the nervous system.
Export Options
About this article
Cite this article as:
Shen Yun, Lu Yun, Yu Fang, Zhu Chuntie, Wang Hua and Wang Jing, Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System, Current Stem Cell Research & Therapy 2016; 11 (3) . https://dx.doi.org/10.2174/1574888X10666150728122034
DOI https://dx.doi.org/10.2174/1574888X10666150728122034 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Current Pharmaceutical Biotechnology Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Current Pharmaceutical Design Hepatitis C Virus-Associated B-Cell Non-Hodgkin's Lymphoma: Clinical and Therapeutic Challenges
Current Drug Targets Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Nanotechnology-Based Drug Delivery Systems for Treatment of Hyperproliferative Skin Diseases - A Review
Current Nanoscience Inhibition of the Tissue Factor Coagulation Pathway
Current Vascular Pharmacology Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Reviews on Recent Clinical Trials Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Current Medicinal Chemistry Impact of Renin-Angiotensin System in Hepatocellular Carcinoma
Current Cancer Drug Targets Extranuclear Effects of Thyroid Hormones in Skeletal Muscle
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Cellular and Molecular Effects of Macrolides on Leukocyte Function
Current Pharmaceutical Design Stem Cells for the Treatment of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy